Herantis Pharma Oyj (HRTIS.HE)
EUR 1.66
(0.91%)
EUR 1.66
(0.91%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | -154.36 Thousand EUR | -101.93% |
| 2022 | 7.99 Million EUR | -57.55% |
| 2021 | 9.04 Million EUR | 54.37% |
| 2020 | 8.07 Million EUR | 12.81% |
| 2019 | 7.15 Million EUR | 46.91% |
| 2018 | 3.66 Million EUR | 154.37% |
| 2017 | 1.02 Million EUR | -56.66% |
| 2016 | 4.41 Million EUR | -72.67% |
| 2015 | 16.16 Million EUR | 111.14% |
| 2014 | 7.65 Million EUR | 917.69% |
| 2013 | 752.43 Thousand EUR | 98.17% |
| 2012 | 382.58 Thousand EUR | -73.58% |
| 2011 | 1.43 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.37 Million EUR | 153.79% |
| 2024 Q2 | 2.75 Million EUR | 0.0% |
| 2023 FY | -154.37 Thousand EUR | -102.92% |
| 2023 Q3 | -1.28 Million EUR | -153.21% |
| 2023 Q4 | -2.56 Million EUR | -99.97% |
| 2023 Q2 | 2.4 Million EUR | 100.0% |
| 2023 Q1 | 1.2 Million EUR | -65.33% |
| 2022 Q2 | 4.52 Million EUR | 106.91% |
| 2022 Q1 | 2.18 Million EUR | -51.56% |
| 2022 FY | 5.28 Million EUR | -57.55% |
| 2022 Q4 | 3.47 Million EUR | 42.1% |
| 2022 Q3 | 2.44 Million EUR | -45.93% |
| 2021 Q4 | 4.51 Million EUR | 86.66% |
| 2021 Q1 | 3.93 Million EUR | 6.75% |
| 2021 FY | 12.46 Million EUR | 54.37% |
| 2021 Q3 | 2.41 Million EUR | -53.81% |
| 2021 Q2 | 5.23 Million EUR | 32.9% |
| 2020 Q2 | 3.54 Million EUR | 76.88% |
| 2020 Q4 | 3.68 Million EUR | 45.47% |
| 2020 FY | 8.07 Million EUR | 12.81% |
| 2020 Q1 | 2 Million EUR | -46.42% |
| 2020 Q3 | 2.53 Million EUR | -28.59% |
| 2019 Q2 | 2.36 Million EUR | 62.62% |
| 2019 Q3 | 2.52 Million EUR | 6.79% |
| 2019 FY | 7.15 Million EUR | 46.91% |
| 2019 Q1 | 1.45 Million EUR | 22.5% |
| 2019 Q4 | 3.74 Million EUR | 48.34% |
| 2018 Q3 | 1.18 Million EUR | -5.61% |
| 2018 Q4 | 1.18 Million EUR | 0.0% |
| 2018 FY | 4.87 Million EUR | 154.37% |
| 2018 Q2 | 1.25 Million EUR | -0.0% |
| 2018 Q1 | 1.25 Million EUR | 1432.79% |
| 2017 FY | 1.91 Million EUR | -56.66% |
| 2017 Q4 | 82.01 Thousand EUR | 0.0% |
| 2017 Q3 | 82.01 Thousand EUR | -91.81% |
| 2017 Q2 | 1 Million EUR | 0.0% |
| 2017 Q1 | 1 Million EUR | -45.8% |
| 2016 Q2 | 1.29 Million EUR | -0.0% |
| 2016 FY | 4.41 Million EUR | -72.67% |
| 2016 Q4 | 1.84 Million EUR | 111.46% |
| 2016 Q3 | 873.61 Thousand EUR | -32.75% |
| 2016 Q1 | 1.29 Million EUR | -46.68% |
| 2015 Q3 | 1.22 Million EUR | -82.16% |
| 2015 FY | 16.16 Million EUR | 111.14% |
| 2015 Q1 | 6.86 Million EUR | 101.86% |
| 2015 Q2 | 6.86 Million EUR | -0.0% |
| 2015 Q4 | 2.43 Million EUR | 98.9% |
| 2014 Q1 | 447.9 Thousand EUR | 248.76% |
| 2014 Q3 | 3.4 Million EUR | 184.84% |
| 2014 Q2 | 1.19 Million EUR | 166.6% |
| 2014 Q4 | 3.4 Million EUR | 0.0% |
| 2014 FY | 7.65 Million EUR | 917.69% |
| 2013 FY | 752.43 Thousand EUR | 98.17% |
| 2013 Q4 | 128.42 Thousand EUR | 0.0% |
| 2013 Q1 | 183.7 Thousand EUR | 0.0% |
| 2013 Q3 | 128.42 Thousand EUR | -58.82% |
| 2013 Q2 | 311.88 Thousand EUR | 69.78% |
| 2012 FY | 379.68 Thousand EUR | -73.58% |
| 2011 FY | 1.43 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biohit Oyj | 6.63 Million EUR | 102.325% |
| Nanoform Finland Oyj | 6.58 Million EUR | 102.343% |